Evidence map›Paper›PMID 40201346›Full record

ArticleFrontiers in oncology2025

Identification of a novel

Jialong Liu, Yaqing Feng, Yanfang Zhang, Yingnan Xiao, Xi Liu, Tingting Xiao, Junyan Zou, Kai Fan, Lisha Lu, Xiaoxia Yang and 1 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jialong Liu *Hematology Pathology Diagnostic Center, TianjinUnion Precision Medical Diagnostics Co. Ltd, Tianjin, China.
Yaqing Feng *Department of Hematology, The Third People's Hospital of Datong City, Datong, Shanxi, China.
Yanfang ZhangDepartment of Hematology, The Third People's Hospital of Datong City, Datong, Shanxi, China.
Yingnan XiaoHematology Pathology Diagnostic Center, TianjinUnion Precision Medical Diagnostics Co. Ltd, Tianjin, China.
Xi LiuDepartment of Hematology, The Third People's Hospital of Datong City, Datong, Shanxi, China.
Tingting XiaoHematology Pathology Diagnostic Center, TianjinUnion Precision Medical Diagnostics Co. Ltd, Tianjin, China.
Junyan ZouHematology Pathology Diagnostic Center, TianjinUnion Precision Medical Diagnostics Co. Ltd, Tianjin, China.
Kai FanDepartment of Hematology, The Third People's Hospital of Datong City, Datong, Shanxi, China.
Lisha LuHematology Pathology Diagnostic Center, TianjinUnion Precision Medical Diagnostics Co. Ltd, Tianjin, China.
Xiaoxia YangDepartment of Hematology, The Third People's Hospital of Datong City, Datong, Shanxi, China.
Jinying GongHematology Pathology Diagnostic Center, TianjinUnion Precision Medical Diagnostics Co. Ltd, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel fusion gene

Indexed as

eosinophiliagene fusionimatinibMLN-TKNRF1PDGFRA rearrangement

Identifiers

PMID40201346
PMCPMC11975939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.